These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

457 related items for PubMed ID: 30239842

  • 1. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842
    [Abstract] [Full Text] [Related]

  • 2. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
    Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS.
    JAMA Oncol; 2017 Mar 01; 3(3):313-319. PubMed ID: 27832260
    [Abstract] [Full Text] [Related]

  • 3. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH.
    J Womens Health (Larchmt); 2018 Mar 01; 27(3):231-237. PubMed ID: 29193980
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
    Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE, EVES Study investigators.
    Maturitas; 2019 Jun 01; 124():55-61. PubMed ID: 31097180
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Balser J, Moyneur É, VVA Prasterone Research Group.
    Menopause; 2016 Mar 01; 23(3):243-56. PubMed ID: 26731686
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.
    Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, Portman D, Montesino M, Côté I, Parent J, Lavoie L, BSc AB, Martel C, Vaillancourt M, Balser J, Moyneur É, members of the VVA Prasterone Research Group.
    Menopause; 2018 Nov 01; 25(11):1339-1353. PubMed ID: 30358731
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a non-hormonal intravaginal moisturizer for the treatment of vaginal dryness in postmenopausal women with sexual dysfunction.
    Vale F, Rezende C, Raciclan A, Bretas T, Geber S.
    Eur J Obstet Gynecol Reprod Biol; 2019 Mar 01; 234():92-95. PubMed ID: 30677618
    [Abstract] [Full Text] [Related]

  • 14. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial.
    Simon JA, Archer DF, Kagan R, Bernick B, Graham S, Constantine GD, Mirkin S.
    Menopause; 2017 Sep 01; 24(9):1003-1010. PubMed ID: 28419068
    [Abstract] [Full Text] [Related]

  • 15. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F, Raichi M.
    Minerva Ginecol; 2016 Jun 01; 68(3):225-36. PubMed ID: 27206062
    [Abstract] [Full Text] [Related]

  • 16. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D, Palacios S, Nappi RE, Mueck AO.
    Maturitas; 2014 Jun 01; 78(2):91-8. PubMed ID: 24679891
    [Abstract] [Full Text] [Related]

  • 17. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
    Vicariotto F, DE Seta F, Faoro V, Raichi M.
    Minerva Ginecol; 2017 Aug 01; 69(4):342-349. PubMed ID: 28608667
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF, Goldstein SR, Simon JA, Waldbaum AS, Sussman SA, Altomare C, Zhu J, Yoshida Y, Schaffer S, Soulban G.
    Menopause; 2019 Jan 28; 26(6):611-621. PubMed ID: 30694917
    [Abstract] [Full Text] [Related]

  • 19. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study.
    Labrie F, Archer DF, Bouchard C, Girard G, Ayotte N, Gallagher JC, Cusan L, Baron M, Blouin F, Waldbaum AS, Koltun W, Portman DJ, Côté I, Lavoie L, Beauregard A, Labrie C, Martel C, Balser J, Moyneur É, Members of the VVA Prasterone Group.
    Maturitas; 2015 May 28; 81(1):46-56. PubMed ID: 25771041
    [Abstract] [Full Text] [Related]

  • 20. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G, Bobula J, Mirkin S.
    Climacteric; 2010 Apr 28; 13(2):132-40. PubMed ID: 19863455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.